Contraception counseling for women with premenstrual dysphoric disorder (PMDD): current perspectives

/

Andrea J Rapkin, Yelena Korotkaya, Kathrine C Taylor 

Open Access Journal of Contraception

Sep 20, 2019

Progestin-only methods including the progestin-only pill (POP), levonorgestrel (LNG) IUD, etonorgestrel implant or depot medroxyprogesterone acetate (DMPA) have the potential to negatively affect mood symptoms for women with or without baseline mood disorders, including PMDD. Careful counseling and close follow-up is recommended for patients with PMDD seeking these contraceptive methods.

Excerpts from Abstract

Premenstrual Dysphoric Disorder (PMDD) is a severe form of premenstrual syndrome (PMS) affecting up to 7% of reproductive age women. Women with PMDD are of reproductive age; therefore, contraception and treatment of PMDD are important considerations. The disorder as described in the DSM-V is characterized by moderate to severe psychological, behavioral and physical symptoms beginning up to two weeks prior to menses, resolving soon after the onset of menstruation and significantly interfering with daily functioning. PMDD develops in predisposed individuals after they are exposed to progesterone at the time of ovulation……..

Conflict of interest statement

Dr Rapkin received payment for serving on an independent Data and Safety Monitoring Board for the Berlin Center for Epidemiology and Health funded by Bayer Pharmaceuticals. He is a member of the Speakers Bureau for Abbvie Pharmaceuticals and for legal reviews. Dr Rapkin also reports personal fees from Bayer Pharmaceuticals, during the conduct of the study. The authors report no other conflicts of interest in this work……….

Read Entire Abstract at PubMed

Open Access Journal of Contraception

by Dovepress

A peer-reviewed, online open access journal publishing original research, reports, reviews and commentaries on all areas of contraception.

References

  1. Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology. 2003;28(Suppl 3):1–23. - PubMed

  2. Hussein Shehadeh J, Hamdan-Mansour AM. Prevalence and association of premenstrual syndrome and premenstrual dysphoric disorder with academic performance among female university students. Perspect Psychiatr Care. 2018;54:176–184. doi:10.1111/ppc.12219 - DOI - PubMed

  3. Sternfeld B, Swindle R, Chawla A, Long S, Kennedy S. Severity of premenstrual symptoms in a health maintenance organization population. Obstet Gynecol. 2002;99:1014–1024. doi:10.1016/s0029-7844(02)01958-0 - DOI - PubMed

  4. Cohen LS, Soares CN, Otto MW, Sweeney BH, Liberman RF, Harlow BL. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles. J Affect Disord. 2002;70:125–132. - PubMed

  5. Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol. 2018;218:68–74. doi:10.1016/j.ajog.2017.05.045 - DOI - PubMed

  6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington (DC): American Psychiatric Association; 2013.

  7. Backstrom T, Andreen L, Birzniece V, et al. The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs. 2003;17:325–342. doi:10.2165/00023210-200317050-00003 - DOI - PubMed

  8. Halbreich U. The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology. 2003;28(Suppl 3):55–99. doi:10.1016/S0306-4530(03)00097-0 - DOI - PubMed

  9. Martinez PE, Rubinow DR, Nieman LK, et al. 5α-reductase inhibition prevents the luteal phase increase in plasma allopregnanolone levels and mitigates symptoms in women with premenstrual dysphoric disorder. Neuropsychopharmacology. 2016;41:1093–1102. doi:10.1038/npp.2015.246 - DOI - PMC - PubMed

  10. Bixo M, Ekberg K, Poromaa IS, et al. Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010) – a randomized controlled trial. Psychoneuroendocrinology. 2017;80:46–55. doi:10.1016/j.psyneuen.2017.02.031 - DOI - PubMed

  11. Gracia CR, Freeman EW, Sammel MD, Lin H, Sheng L, Frye C. Allopregnanolone levels before and after selective serotonin reuptake inhibitor treatment of premenstrual symptoms. J Clin Psychopharmacol. 2009;29:403–405. doi:10.1097/JCP.0b013e3181ad8825 - DOI - PubMed

  12. Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med. 2001;10:561–569. doi:10.1089/15246090152543148 - DOI - PubMed

  13. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005;72:414–421. doi:10.1016/j.contraception.2005.08.021 - DOI - PubMed

  14. Halbreich U, Freeman EW, Rapkin AJ, et al. Continuous oral levonorgestrel/ethinyl estradiol for treating premenstrual dysphoric disorder. Contraception. 2012;85:19–27. doi:10.1016/j.contraception.2011.05.008 - DOI - PubMed

  15. Freeman EW, Halbreich U, Grubb GS, et al. An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception. 2012;85:437–445. doi:10.1016/j.contraception.2011.09.010 - DOI - PubMed

  16. Naheed B, Kuiper JH, Uthman OA, O’Mahony F, O’Brien PM. Non-contraceptive oestrogen-containing preparations for controlling symptoms of premenstrual syndrome. Cochrane Database Syst Rev. 2017;3:Cd010503. - PMC - PubMed

  17. Ford O, Lethaby A, Roberts H, Mol BW. Progesterone for premenstrual syndrome. Cochrane Database Syst Rev. 2012;Cd003415. - PMC - PubMed

  18. O’Brien PM, Backstrom T, Brown C, et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch Womens Ment Health. 2011;14:13–21. doi:10.1007/s00737-010-0201-3 - DOI - PMC - PubMed

  19. Nevatte T, O’Brien PM, Backstrom T, et al. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health. 2013;16:279–291. doi:10.1007/s00737-013-0346-y - DOI - PMC - PubMed

  20. Ismaili E, Walsh S, O’Brien PMS, et al. Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder. Arch Womens Ment Health. 2016;19:953–958. doi:10.1007/s00737-016-0631-7 - DOI - PubMed

  21. Kadian S, O’Brien S. Classification of premenstrual disorders as proposed by the International Society for Premenstrual Disorders. Menopause Int. 2012;18:43–47. doi:10.1258/mi.2012.012017 - DOI - PubMed

  22. Green L, O’Brien PMS, Panay N, Craig M. Royal College of Obstetrics and Gynecologists. Management of premenstrual syndrome. BJOG. 2017;124:e73–e105. - PubMed

  23. Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Womens Ment Health. 2003;6:203–209. doi:10.1007/s00737-003-0018-4 - DOI - PubMed

  24. Steiner M, Peer M, Palova E, Freeman EW, Macdougall M, Soares CN. The Premenstrual Symptoms Screening Tool revised for adolescents (PSST-A): prevalence of severe PMS and premenstrual dysphoric disorder in adolescents. Arch Womens Ment Health. 2011;14:77–81. doi:10.1007/s00737-010-0202-2 - DOI - PubMed

  25. Henz A, Ferreira CF, Oderich CL, et al. Premenstrual syndrome diagnosis: a comparative study between the Daily Record of Severity of Problems (DRSP) and the Premenstrual Symptoms Screening Tool (PSST). Rev Bras Ginecol Obstet. 2018;40:20–25. doi:10.1055/s-0037-1608672 - DOI - PubMed

  26. Pearlstein T, Steiner M. Premenstrual dysphoric disorder: burden of illness and treatment update. J Psychiatry Neurosci. 2008;33:291–301. - PMC - PubMed

  27. Gehlert S, Song IH, Chang C-H, Hartlage SA. The prevalence of premenstrual dysphoric disorder in a randomly selected group of urban and rural women. Psychol Med. 2009;39:129–136. doi:10.1017/S003329170800322X - DOI - PMC - PubMed

  28. Halbreich U, Backstrom T, Eriksson E, et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol. 2007;23:123–130. doi:10.1080/09513590601167969 - DOI - PubMed

  29. Yonkers KA, Pearlstein T, Rosenheck RA. Premenstrual disorders: bridging research and clinical reality. Arch Womens Ment Health. 2003;6:287–292. doi:10.1007/s00737-003-0026-4 - DOI - PubMed

  30. Endicott J. Premenstrual Dysphorias: Myths and Realities. Washington (DC): American Psychiatric Press; 1994.

  31. Critchlow DG, Bond AJ, Wingrove J. Mood disorder history and personality assessment in premenstrual dysphoric disorder. J Clin Psychiatry. 2001;62:688–693. - PubMed

  32. Pearlstein TB, Frank E, Rivera-Tovar A, Thoft JS, Jacobs E, Mieczkowski TA. Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. J Affect Disord. 1990;20:129–134. - PubMed

  33. Yonkers KA. The association between premenstrual dysphoric disorder and other mood disorders. J Clin Psychiatry. 1997;58(Suppl 15):19–25. - PubMed

  34. Watson NR, Studd JW, Savvas M, Garnett T, Baber RJ. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet. 1989;2:730–732. doi:10.1016/s0140-6736(89)90784-8 - DOI - PubMed

  35. Schmidt PJ, Martinez PE, Nieman LK, et al. Premenstrual dysphoric disorder symptoms following ovarian suppression: triggered by change in ovarian steroid levels but not continuous stable levels. Am J Psychiatry. 2017;174:980–989. doi:10.1176/appi.ajp.2017.16101113 - DOI - PMC - PubMed

  36. Hatcher R. Contraceptive Technology. 21st ed. Bridging the Gap Communications; 2018.

  37. Bixo M, Johansson M, Timby E, Michalski L, Backstrom T. Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder. J Neuroendocrinol. 2018;30:e12553. doi:10.1111/jne.12553 - DOI - PubMed

  38. Backstrom T, Bixo M, Johansson M, et al. Allopregnanolone and mood disorders. Prog Neurobiol. 2014;113:88–94. doi:10.1016/j.pneurobio.2013.07.005 - DOI - PubMed

  39. Sundstro II, Backstrom T. Citalopram increases pregnanolone sensitivity in patients with premenstrual dysphoric disorder. Acta Physiol Scand. 1999;167:A6–A7. doi:10.1046/j.1365-201x.1999.0600f.x - DOI - PubMed

  40. Luscher B, Shen Q, Sahir N. The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry. 2011;16:383–406. doi:10.1038/mp.2010.120 - DOI - PMC - PubMed

  41. Maguire J. Neuroactive steroids and GABAergic involvement in the neuroendocrine dysfunction associated with major depressive disorder and postpartum depression. Front Cell Neurosci. 2019;13:83. doi:10.3389/fncel.2019.00083 - DOI - PMC - PubMed

  42. Lundin C, Danielsson KG, Bixo M, et al. Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle – a double-blind, placebo-controlled randomized trial. Psychoneuroendocrinology. 2017;76:135–143. doi:10.1016/j.psyneuen.2016.11.033 - DOI - PubMed

  43. Giatti S, Melcangi RC, Pesaresi M. The other side of progestins: effects in the brain. J Mol Endocrinol. 2016;57:R109–R126. doi:10.1530/JME-16-0061 - DOI - PubMed

  44. Bixo M, Allard P, Backstrom T, et al. Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment. Psychoneuroendocrinology. 2001;26:551–564. - PubMed

  45. Uzunova V, Sheline Y, Davis JM, et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA. 1998;95:3239–3244. doi:10.1073/pnas.95.6.3239 - DOI - PMC - PubMed

  46. Uzunova V, Sampson L, Uzunov DP. Relevance of endogenous 3alpha-reduced neurosteroids to depression and antidepressant action. Psychopharmacology (Berl). 2006;186:351–361. doi:10.1007/s00213-005-0201-6 - DOI - PubMed

  47. Eriksson E. SSRIs probably counteract premenstrual syndrome by inhibiting the serotonin transporter. J Psychopharmacol. 2014;28:173–174. doi:10.1177/0269881113512910 - DOI - PubMed

  48. Menkes DB, Coates DC, Fawcett JP. Acute tryptophan depletion aggravates premenstrual syndrome. J Affect Disord. 1994;32:37–44. - PubMed

  49. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry. 1999;56:932–939. doi:10.1001/archpsyc.56.10.932 - DOI - PubMed

  50. Liu B, Liu J, Wang M, Zhang Y, Li L. From serotonin to neuroplasticity: evolvement of theories for major depressive disorder. Front Cell Neurosci. 2017;11:305. doi:10.3389/fncel.2017.00305 - DOI - PMC - PubMed

  51. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology. 2008;33:88–109. doi:10.1038/sj.npp.1301574 - DOI - PubMed

  52. Dimmock PW, Wyatt KM, Jones PW, O’Brien PM. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet. 2000;356:1131–1136. doi:10.1016/s0140-6736(00)02754-9 - DOI - PubMed

  53. Wyatt KM, Dimmock PW, O’Brien PM. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2002;Cd001396. - PubMed

  54. Marjoribanks J, Brown J, O’Brien PM, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2013;Cd001396.>. - PMC - PubMed

  55. Steiner M, Pearlstein T, Cohen LS, et al. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. J Womens Health (Larchmt). 2006;15:57–69. doi:10.1089/jwh.2006.15.57 - DOI - PubMed

  56. Yonkers KA, Holthausen GA, Poschman K, Howell HB. Symptom-onset treatment for women with premenstrual dysphoric disorder. J Clin Psychopharmacol. 2006;26:198–202. doi:10.1097/01.jcp.0000203197.03829.ae - DOI - PubMed

  57. Busse JW, Montori VM, Krasnik C, Patelis-Siotis I, Guyatt GH. Psychological intervention for premenstrual syndrome: a meta-analysis of randomized controlled trials. Psychother Psychosom. 2009;78:6–15. doi:10.1159/000162296 - DOI - PubMed

  58. Lustyk MK, Gerrish WG, Shaver S, Keys SL. Cognitive-behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch Womens Ment Health. 2009;12:85–96. doi:10.1007/s00737-009-0052-y - DOI - PubMed

  59. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106:492–501. doi:10.1097/01.AOG.0000175834.77215.2e - DOI - PubMed

  60. Lopez LM, Kaptein A, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2008;Cd006586. - PubMed

  61. Backstrom T, Hansson-Malmstrom Y, Lindhe BA, Cavalli-Bjorkman B, Nordenstrom S. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception. 1992;46:253–268. doi:10.1016/0010-7824(92)90006-f - DOI - PubMed

  62. Smith RN, Studd JW, Zamblera D, Holland EF. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol. 1995;102:475–484. doi:10.1111/j.1471-0528.1995.tb11321.x - DOI - PubMed

  63. Sondheimer SJ. Oral contraceptives: mechanism of action, dosing, safety, and efficacy. Cutis. 2008;81:19–22. - PubMed

  64. McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception. 1994;50:S1–S195. - PubMed

  65. Attia AM, Ibrahim MM, Abou-Setta AM. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence. 2013;7:777–785. doi:10.2147/PPA.S36948 - DOI - PMC - PubMed

  66. ACOG Committee Opinion No. 735. Adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 2018;131:e130–e139. doi:10.1097/AOG.0000000000002632 - DOI - PubMed

  67. Duke JM, Sibbritt DW, Young AF. Is there an association between the use of oral contraception and depressive symptoms in young Australian women? Contraception. 2007;75:27–31. doi:10.1016/j.contraception.2006.08.002 - DOI - PubMed

  68. Toffol E, Heikinheimo O, Koponen P, Luoto R, Partonen T. Hormonal contraception and mental health: results of a population-based study. Hum Reprod. 2011;26:3085–3093. doi:10.1093/humrep/der269 - DOI - PubMed

  69. Keyes KM, Cheslack-Postava K, Westhoff C, et al. Association of hormonal contraceptive use with reduced levels of depressive symptoms: a national study of sexually active women in the United States. Am J Epidemiol. 2013;178:1378–1388. doi:10.1093/aje/kwt188 - DOI - PMC - PubMed

  70. Toffol E, Heikinheimo O, Koponen P, Luoto R, Partonen T. Further evidence for lack of negative associations between hormonal contraception and mental health. Contraception. 2012;86:470–480. doi:10.1016/j.contraception.2012.02.014 - DOI - PubMed

  71. Schaffir J, Worly BL, Gur TL. Combined hormonal contraception and its effects on mood: a critical review. Eur J Contracept Reprod Health Care. 2016;21:347–355. doi:10.1080/13625187.2016.1217327 - DOI - PubMed

  72. Poromaa IS, Segebladh B. Adverse mood symptoms with oral contraceptives. Acta Obstet Gynecol Scand. 2012;91:420–427. doi:10.1111/j.1600-0412.2011.01333.x - DOI - PubMed

  73. Bengtsdotter H, Lundin C, Gemzell Danielsson K, et al. Ongoing or previous mental disorders predispose to adverse mood reporting during combined oral contraceptive use. Eur J Contracept Reprod Health Care. 2018;23:45–51. doi:10.1080/13625187.2017.1422239 - DOI - PubMed

  74. Skovlund CW, Morch LS, Kessing LV, Lidegaard O. Association of hormonal contraception with depression. JAMA Psychiatry. 2016;73:1154–1162. doi:10.1001/jamapsychiatry.2016.2387 - DOI - PubMed

  75. Berry-Bibee EN, Kim M-J, Simmons KB, et al. Drug interactions between hormonal contraceptives and psychotropic drugs: a systematic review. Contraception. 2016;94:650–667. doi:10.1016/j.contraception.2016.07.011 - DOI - PubMed

  76. Aleknaviciute J, Tulen JHM, De Rijke YB, et al. The levonorgestrel-releasing intrauterine device potentiates stress reactivity. Psychoneuroendocrinology. 2017;80:39–45. doi:10.1016/j.psyneuen.2017.02.025 - DOI - PubMed

  77. Seeber B, Ziehr SC, Gschlieβer A, et al. Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system. Contraception. 2012;86:345–349. doi:10.1016/j.contraception.2012.01.015 - DOI - PubMed

  78. Merki-Feld GS, Apter D, Bartfai G, et al. ESC expert statement on the effects on mood of the natural cycle and progestin-only contraceptives. Eur J Contracept Reprod Health Care. 2017;22:247–249. doi:10.1080/13625187.2017.1353075 - DOI - PubMed

  79. Pagano HP, Zapata LB, Berry-Bibee EN, Nanda K, Curtis KM. Safety of hormonal contraception and intrauterine devices among women with depressive and bipolar disorders: a systematic review. Contraception. 2016;94:641–649. doi:10.1016/j.contraception.2016.06.012 - DOI - PubMed

  80. Nilsson CG, Lahteenmaki PL, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril. 1984;41:52–55. - PubMed

  81. Kailasam C, Cahill D. Review of the safety, efficacy and patient acceptability of the levonorgestrel-releasing intrauterine system. Patient Prefer Adherence. 2008;2:293–302. - PMC - PubMed

  82. Tewari R, Kay VJ. Compliance and user satisfaction with the intra-uterine contraceptive device in Family Planning Service: the results of a survey in Fife, Scotland, August 2004. Eur J Contracept Reprod Health Care. 2006;11:28–37. doi:10.1080/13625180500431422 - DOI - PubMed

  83. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception. 1994;49:56–72. doi:10.1016/0010-7824(94)90109-0 - DOI - PubMed

  84. Sivin I, el Mahgoub S, McCarthy T, et al. Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study. Contraception. 1990;42:361–378. doi:10.1016/0010-7824(90)90046-x - DOI - PubMed

  85. Berenson AB, Asem H, Tan A, Wilkinson GS. Continuation rates and complications of intrauterine contraception in women diagnosed with bipolar disorder. Obstet Gynecol. 2011;118:1331–1336. doi:10.1097/AOG.0b013e318233beae - DOI - PMC - PubMed

  86. Smith K, Nayyar S, Rana T, Archibong AE, Looney KR, Nayyar T. Do progestin-only contraceptives contribute to the risk of developing depression as implied by beta-arrestin 1 levels in leukocytes? A pilot study. Int J Environ Res Public Health. 2018;15. doi:10.3390/ijerph15061188 - DOI - PMC - PubMed

  87. Worly BL, Gur TL, Schaffir J. The relationship between progestin hormonal contraception and depression: a systematic review. Contraception. 2018;97:478–489. doi:10.1016/j.contraception.2018.01.010 - DOI - PubMed

  88. Gregory ST, Hall K, Quast T, et al. Hormonal contraception, depression, and academic performance among females attending college in the United States. Psychiatry Res. 2018;270:111–116. doi:10.1016/j.psychres.2018.09.029 - DOI - PubMed

  89. Francis J, Presser L, Malbon K, Braun-Courville D, Linares LO. An exploratory analysis of contraceptive method choice and symptoms of depression in adolescent females initiating prescription contraception. Contraception. 2015;91:336–343. doi:10.1016/j.contraception.2014.12.010 - DOI - PubMed

  90. ACOG Committee Opinion No. 757. Summary: screening for perinatal depression. Obstet Gynecol. 2018;132:1314–1316. doi:10.1097/AOG.0000000000002928 - DOI - PubMed

  91. Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65:1–103. - PubMed